Although specific molecular testing for mTOR pathway genes was not performed in our case, the existing literature indicates frequent alterations in the TSC/MTOR pathway in RCC-FMS (Table 2), which is characterized by frequent expression of CK7 (100%), CD10 (87.5%), Vimentin (100%), and CA IX (100%) in the limited number of cases with available data. The gene discussed is CA9; the disease is renal cell carcinoma.